<DOC>
	<DOCNO>NCT01351415</DOCNO>
	<brief_summary>This open-label , randomize , multicenter study evaluate efficacy safety bevacizumab ( Avastin ) combination standard care ( SOC ) treatment participant advance non-squamous NSCLC . Participants enrol documentation progression disease ( PD ) 4-6 cycle first-line treatment bevacizumab plus platinum doublet-containing therapy minimum two cycle bevacizumab maintenance treatment prior PD . Participants randomly assign one two treatment arm receive either bevacizumab plus SOC treatment SOC treatment alone .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With Standard Care Treatment Participants With Advanced Non-squamous Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm nonsquamous NSCLC Documented progression disease ( locally recurrent metastatic ) per investigator assessment follow firstline treatment 46 cycle Bevacizumab plus platinum doubletcontaining chemotherapy regimen minimum 2 cycle Bevacizumab ( monotherapy ) maintenance treatment prior first progression disease No treatment interruption Bevacizumab treatment great 2 consecutive cycle ( 42 day ) start firstline treatment start Cycle 1 second line treatment Randomization within 4 week progression disease At least one unidimensionally measurable lesion meeting RECIST v1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Participants adequate hematological , liver , renal function Female participant must pregnant breastfeeding . Female participant childbearing potential fertile male participant must agree use highly effective contraceptive trial period least 6 month follow last administration trial drug ( ) Mixed , nonsmall cell small cell tumor mix adenosquamous carcinoma predominant squamous component Epidermal growth factor receptor ( EGFR ) mutationpositive disease accord local laboratory test History hemoptysis great equal ( &gt; /= ) grade 2 within 3 month randomization History evidence inherit bleed diathesis coagulopathy risk bleed active gastrointestinal bleeding Major cardiac disease Treatment investigational agent within 28 day prior randomization Known hypersensitivity bevacizumab excipients , SOC drug foreseen Malignancy NSCLC within 5 year prior randomization evidence disease contraindicates use investigational SOC drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>